Back to Search Start Over

Treatment of former smokers with 9-cis-retinoic acid reverses loss of retinoic acid receptor-beta expression in the bronchial epithelium: results from a randomized placebo-controlled trial.

Authors :
Kurie JM
Lotan R
Lee JJ
Lee JS
Morice RC
Liu DD
Xu X
Khuri FR
Ro JY
Hittelman WN
Walsh GL
Roth JA
Minna JD
Hong WK
Kurie, Jonathan M
Lotan, Reuben
Lee, J Jack
Lee, Jin Soo
Morice, Rodolfo C
Liu, Diane D
Source :
JNCI: Journal of the National Cancer Institute. 2/5/2003, Vol. 95 Issue 3, p206-214. 9p.
Publication Year :
2003

Abstract

<bold>Background: </bold>Loss of retinoic acid receptor beta (RAR-beta) expression in the bronchial epithelium is considered a biomarker of preneoplasia. Retinoids can restore expression of this receptor and, presumably, halt the progression of carcinogenesis. This study was designed to investigate whether either of two retinoid-based regimens, 9-cis-retinoic acid (RA) or 13-cis-RA plus alpha-tocopherol (AT), could reverse RAR-beta expression loss in former smokers after 3 months of treatment.<bold>Methods: </bold>Individuals (n = 226) who had smoked at least 20 pack-years and had ceased smoking for at least 12 months were randomly assigned to receive 3 months of daily oral 9-cis-RA (100 mg), 13-cis-RA (1 mg/kg) + AT (1200 IU), or placebo. Bronchoscopy and biopsy at six predetermined sites of the bronchial tree were performed before treatment and at 3 and 6 months thereafter. Specimens were evaluated for squamous metaplasia, dysplasia, and RAR-beta expression. McNemar's test was used to test changes in RAR-beta expression and squamous metaplasia within each treatment group, and a generalized estimating equations model was applied to model the treatment effect, adjusting for covariates. All statistical tests were two-sided.<bold>Results: </bold>A total of 177 assessable subjects completed at least 3 months of therapy and underwent at least the baseline and 3-month bronchoscopic evaluations with biopsies. RAR-beta was detected in 69.7% of all baseline biopsy samples, and metaplasia was evident in 6.9% of all baseline samples from 240 subjects. Restoration of RAR-beta expression (P =.03) and reduction of metaplasia (P =.01) were found in the 9-cis-RA group. After adjustment for years of smoking, packs/day smoked, and metaplasia, treatment with 9-cis-RA, but not with 13-cis-RA + AT, led to a statistically significant increase in RAR-beta expression compared with placebo (P =.03).<bold>Conclusion: </bold>9-cis-RA treatment can restore RAR-beta expression in the bronchial epithelium of former smokers, raising the possibility that this retinoid has potential chemopreventive properties in former smokers. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
00278874
Volume :
95
Issue :
3
Database :
Academic Search Index
Journal :
JNCI: Journal of the National Cancer Institute
Publication Type :
Academic Journal
Accession number :
106694851
Full Text :
https://doi.org/10.1093/jnci/95.3.206